New salvage vincristine, carmustine, cyclophosphamide, and prednisone (VBCP) chemotherapy for relapsed/refractory multiple myeloma in the modern era: A case series
Journal Title: Journal of Cancer Research & Therapy - Year 2017, Vol 5, Issue 10
Abstract
We report our experience with vincristine, carmustine (BCNU), cyclophosphamide, and prednisone (VBCP), a regimen given in the outpatient setting to patients with multiple myeloma (MM) resistant to almost all the available novel/targeted therapies. Ten patients received salvage VBCP who were heavily pretreated with a median of 5.5 prior treatment regimens including lenalidomide, pomalidomide, bortezomib, carfilzomib, cyclophosphamide, and autologous stem cell transplantation. The objective response rate (≥PR) was 60%, with an additional 30% achieving stable disease (SD). The median time to progression for patients with ≥SD was 3.6 months. The median progression free survival was 4.4 months while the median overall survival was 12.8 months. Despite severe myelosuppression being the main toxicity, 61% of the subsequent cycles were given on time. Treatment-related mortality was not observed. Our results suggest VBCP is a highly active and tolerable salvage regimen among heavily pretreated MM patients who already failed many of the novel agents.
Authors and Affiliations
Abdullah M Khan, Jameel Muzaffar, Lazarus K Mramba, Jan S Moreb
Keywords
Related Articles
- EP ID EP539255
- DOI 10.14312/2052-4994.2017-12
- Views 62
- Downloads 0
Body composition, somatotype and risk of premenopausal breast cancer: a case-control study in Uruguay
In order to analyze detailed anthropometric characterisation for risk of breast cancer (BC) in premenopausal Uruguayan women, a case-control study was carried out at the Pereira Rossell Women’s Hospital, Montevideo, wher...
Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?
Background: Skin rash during treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) has been reported to be predictive for response and survival in patients with advanced non-small cell l...
Treatment of an atypical metastatic meningioma: a case report
Meningiomas are common intracranial tumors which usually pursue a benign course. Extracranial metastases from meningiomas are very rare and the lung is the most common site. We report a 27 year old girl with an intracran...
The prevention and treatment of peritoneal carcinomatosis from gastric cancer: A 2013 update
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death in the world. Penetration of the gastric serosa and lymphatic spread are the two most important factors affecting prognosis in...
Capecitabine induced hypertriglyceridaemia: An underreported and potentially severe side effect
A 57 year-old-woman, with no previous history of dyslipedemia, developed severe hypertriglyceridemia while being treated with capecitabine for metastatic breast cancer. Capecitabine was not discontinued and serum triglyc...